Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245230 · ClinicalTrials.gov registry record · Phase 1
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
A Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02245230: Clinical Trial Phase 1 study, sponsored by Vanderbilt University.
NCT02245230 is a Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02245230, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand the cardiovascular effects of the vasodilatory peptide Angiotensin (1-7) in human hypertension. In this study, the investigators will test the hypothesis that systemic Angiotensin (1-7) infusion produces negligible effects with intact baroreceptors, and that the cardiovascular effects of this peptide are unmasked following elimination of baroreflex buffering.
Primary Outcome
The primary outcome will be the change in systolic blood pressure from baseline produced by the Angiotensin (1-7) infusion, with comparisons made between intact and autonomic blockade study days.
Interventions
- DRUG Angiotensin (1-7)
- DRUG Phenylephrine
- DRUG Trimethaphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-01 |
| Est. Completion | 2023-12 |
| Phase | Phase 1 |
Why NCT02245230 stopped before completion
NCT02245230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 3 interventions - of which Angiotensin (1-7) is the first listed.
NCT02245230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02245230 about?
NCT02245230 is a clinical study titled "Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension". The purpose of this study is to better understand the cardiovascular effects of the vasodilatory peptide Angiotensin (1-7) in human hypertension. In this study, the investigators will test the hypothesis that systemic Angiotensin (1-7) infusion produces negligible effects with intact baroreceptors, ...
What is the current status of trial NCT02245230?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-01. Estimated completion is 2023-12.
What interventions are being tested in trial NCT02245230?
The interventions under investigation include: Angiotensin (1-7) (DRUG), Phenylephrine (DRUG), Trimethaphan (DRUG).
Who is sponsoring clinical trial NCT02245230?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02245230's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia